Funding supports commercial expansion of inHEART's digital
twin of the heart in the US, EU, Asia
Pacific, and Middle East
markets, as well as the development of new software solutions
across the cardiac care continuum
CAMBRIDGE, Mass. and
BORDEAUX, France, May 6, 2024 /PRNewswire/ -- inHEART, a medical
device company delivering the world's most advanced, AI-driven
digital twin of the heart, has raised $11M to drive commercial growth of its
therapeutic software solution for cardiac ablation procedures and
advance the development of its predictive cardiac models for heart
failure, sudden cardiac death, and cardio-embolic stroke.
The financing was led by Vesalius Biocapital IV and co-led
by Elaia Partners with participation from NACO, Sagana, Sofia Angel
Ventures, CWR Funds, and Webit Investment Network. In addition,
inHEART received funds from a successful crowdequity campaign on
Tudigo and from the UK impact fund Astorg Foundation.
"We welcome this strong international group of investors to our
latest round of financing," said Todor Jeliaskov, Chairman and CEO
of inHEART. "This new round allows us to go further in addressing
the needs of cardiac patients from early screening and disease
detection through advanced therapeutic support. It's exciting for
us to be at the forefront of transforming the healthcare industry
with the power of AI technology by improving the efficiency of
care, quality of decision-making, and effectiveness and safety of
medical interventions."
"We are enthusiastic to continue our support and co-lead this
financing round for inHEART," said Samantha Jérusalmy, board member
at inHEART and Partner at Elaia. "inHEART's AI-driven 3D cardiac
mapping enables unprecedented precision in targeting and treating
arrhythmias, setting new standards in the treatment of heart
conditions."
"At Vesalius Biocapital IV, we're dedicated to supporting
advancements in medical technology that improve patient care." said
Jean-Christophe Renondin, Managing Partner at Vesalius Biocapital
IV. "inHEART's AI-driven solutions exemplify the future of cardiac
care, offering personalized therapy options and predictive models
that can enhance clinical outcomes and streamline treatment
processes. We're excited to contribute to inHEART's journey as they
revolutionize cardiac care and address global healthcare needs with
cutting-edge technology and innovation."
Optimizing cardiac care
inHEART's current therapeutic solution addresses the challenges
of conventional cardiac ablations. The inHEART solution creates
highly detailed, interactive 3D heart models with proprietary
AI-driven cardiac CT or MR image segmentation. These 3D models of
the heart allow physicians to optimize treatment strategies based
on each patient's unique cardiac anatomy and to support
pre-procedural planning for faster ablation procedures and improved
clinical outcomes.
AI-driven predictive models
Financing from this round will also support the development of
new product verticals for AI-driven predictive software models for
sudden cardiac death and cardio-embolic stroke, as well as a new
therapeutic software solution to help physicians treat heart
failure patients. Currently, inHEART is commercially available in
the US and EU through a direct sales force model, with plans to
establish a global distribution network in the coming months to
further accelerate growth.
About inHEART
inHEART is delivering the world's first AI-driven, digital twin
of the heart to advance the care of patients living with cardiac
disease. We are committed to addressing the needs of the cardiac
care continuum by providing personalized therapy in a predictive
manner for screening and early detection of cardiac diseases. At
inHEART, we believe all patients deserve access to world-class
cardiac imaging expertise to optimize treatment strategies,
improve clinical outcomes, and return patients to full, healthy
lives. For more information, visit inheartmedical.com
Logo -
https://mma.prnewswire.com/media/1806866/inHEART.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/inheart-raises-11m-to-accelerate-development--deployment-of-novel-therapeutic-predictive-and-screening-cardiac-solutions-302136710.html